Cat. No. 3026
Alternative Name: Pranlukast
Chemical Name: N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-
Biological ActivitySelective cysteinyl leukotriene receptor 1 (CysLT1) antagonist (IC50 values are ~ 4 - 7 and 3620 nM for CysLT1 and CysLT2 respectively). Inhibits contraction of airway smooth muscle, microvascular leakage into airways and eosinophil infiltration. Can decrease symptoms of bronchial asthma.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Suzuki et al (2003) Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (Pranlukast; ONO-1078). J.Asthma 40 395. PMID: 12870835.
Heise et al (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J.Biol.Chem. 275 30531. PMID: 10851239.
Lynch et al (1999) Characterization of the human leukotriene CysLT1 receptor. Nature 399 789. PMID: 10391245.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ONO 1078 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: ONO 1078, supplier, Selective, CysLT1, antagonists, Receptors, leukotrienes, eicosanoids, ONO1078, Tocris Bioscience, Leukotriene and Related Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally available
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.